Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Are Investors Wrong About Celldex Therapeutics?

Short interest is an important factor to consider when investing in any stock. Within the biotech sphere, rising short interest could signal a pending clinical failure or regulatory setback, making it a vital metric to keep a close watch on. 

Celldex Therapeutics (NASDAQ: CLDX  ) is a clinical-stage biopharma focusing primarily on the development of new cancer treatments. Despite advancing its lead drugs into mid- and late-stage testing for potential blockbuster indications, short-sellers have piled into this stock this year. And perhaps correlated with this rising short interest, Celldex shares have fallen a noteworthy 28% year to date. With this in mind, let's consider two reasons shorts are targeting this mid-cap biopharma. 

CLDX Chart

CLDX data by YCharts

Reason No. 1
Celldex's most advanced clinical candidate, rindopepimut, is indicated as a potential treatment for glioblastoma multiforme, a particularly aggressive and difficult-to-treat form of brain cancer.  What's key to understand is that numerous experimental treatments for glioblastoma have failed in clinical trials over the years. Roche's Avastin was the first pharmaceutical approved by the Food and Drug Administration to treat any form of glioblastoma in over a decade, and even it can only claim marginal clinical benefits for this terrible disease. 

Although rindopepimut did show encouraging signs of improving survival rates and progression-free survival compared to historical benchmarks in a mid-stage study, we have seen similar results from other drugs that went on to fail in late-stage studies. Put simply, shorts are betting that rindopepimut will ultimately fail in its quest to become a breakthrough treatment for this devastating form of cancer.

Reason No. 2
The company's second most advanced clinical candidate, Glembatumumab vedotin, is based on Seattle Genetics' (NASDAQ: SGEN  )  promising antibody-drug conjugate, or ADC, technology that consists of a human monoclonal antibody linked to a potent cellular toxin. Glembatumumab is being tested as a potential treatment for breast cancer and melanoma.

Although Roche, Seattle Genetics, and others have invested heavily in this technology for nearly two decades, we have only seen a handful of approvals so far. Moreover, the first ADC to be approved, Mylotarg, was withdrawn from the market due to serious adverse events. 

The problem is that off-site toxicity issues haven't been completely resolved and researchers are still working on ways to improve tissue targeting for ADCs. So while Celldex is pursuing a hot-ticket item in oncology research with Glembatumumab, the technology is far from perfect. The short thesis would thus appear to be that Glembatumumab won't succeed where the majority of experimental ADCs have failed. Time will tell. 

Foolish wrap-up
Celldex has decided to target two of the hottest areas in oncology with its lead clinical candidates, namely immunotherapy and ADCs. Moreover, these drugs are indicated for diseases that have strong growth prospects going forward. It's therefore not surprising that investors once pushed Celldex's market cap to above $3 billion at one point last year. Now that some of the enthusiasm for clinical-stage biopharmas has worn off and investors are looking more toward actual revenue streams, Celldex has fallen by more than 50% from its former highs.

Viewed in this light, Celldex might now be considered a bargain. The high and rising short interest, however, shouldn't be ignored. In my view, Celldex's management has decided to plot a high-reward, high-risk course for its clinical program. And they should be applauded for pursuing treatments for diseases like Glioblastoma that have proven to be very difficult to treat with pharmaceuticals.

That being said, the company is a way away from reporting data from a clinical trial that could be used to gain approval (its phase 3 trial will report out in late 2016, according to, and the risk of failure for these indications is perhaps higher than usual. Consequently, I think investors with a long-term outlook would be best served by taking a wait-and-see approach with this one. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.


Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 10, 2014, at 10:32 PM, Russo420 wrote:

    This stock is a screaming buy! Over 17M shorts with an 89M float. Good luck to the shorts trying to cover. They will be paying over 40/share within a year. Watch, or better yet buy!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3018626, ~/Articles/ArticleHandler.aspx, 8/30/2015 12:12:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
CLDX $15.36 Up +0.25 +1.65%
Celldex Therapeuti… CAPS Rating: ****
SGEN $42.25 Up +1.01 +2.45%
Seattle Genetics CAPS Rating: ***